Navigation Links
YM BioSciences enrolls first US patient in Phase II randomized, double-blind brain metastases trial for nimotuzumab
Date:5/27/2010

ctively target cancer cells resulting in improvements to the safety profiles of antibodies and the consequent prospect of their conjugation to highly potent toxins for safe delivery to tumour tissue. YM is also developing AeroLEF for the treatment of moderate to severe acute pain. The product is differentiated from other approaches using opioids because patients are able to individually control the analgesia required for their differing intensities of pain. AeroLEF has met all endpoints in each of its trials including a randomized Phase II trial and is currently being prepared for late-stage development internationally.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that JAK 1/2 and the VDA molecule will generate positive efficacy and safety data in future clinical trials; AeroLEF(R) will continue to generate positive efficacy and safety data in future clinical trials; and that YM and its various partners will complete their respective clinical trials within the timelines communic
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Regado Biosciences, Inc. Continues to Expand Its Patent Portfolio By Announcing Issuance of a New Patent for Its Product Candidates, the REG1 and REG2 Anticoagulation Systems
2. Sangamo BioSciences and Collaborators Present Data in Fifteen Presentations Highlighting Broad Therapeutic Applications of ZFP Technology
3. YM BioSciences announces presentations on global nimotuzumab trials at ASCO annual meeting
4. YM BioSciences third quarter 2010 operational and financial results
5. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
6. Regado Biosciences to Present at the BIO International Convention Held in Chicago, Illinois on May 5, 2010
7. YM BioSciences announces controlled equity offering
8. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2010 Financial Results
9. NeoStem, Inc. and ImmuneRegen BioSciences(R) Announce a Collaborative Agreement to Advance Stem Cell Technology
10. Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering
11. YM BioSciences announces AACR acceptance of two nimotuzumab poster presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... (PRWEB) July 24, 2014 Gain ... Global Supply Chain of the biotech industry. Nominations ... Innovation Awards, brought to you by the ... organization of supply chain management professionals for the ... to stakeholders of the Biotech industry – Manufacturers, ...
(Date:7/24/2014)... , July 24, 2014  Asterias Biotherapeutics, ... the emerging field of regenerative medicine, announced today ... a presentation to investors on Tuesday, July 29, ...  The presentation will include an overview of Asterias, ... the webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics at least ...
(Date:7/24/2014)... on sophisticated equipment, trained personnel, and detection dogs ... terrorist attacks. A revolutionary new electronic chip with ... job much easier. , The groundbreaking nanotechnology-inspired sensor, ... University ,s School of Chemistry and Center for ... company Tracense, picks up the scent of explosives ...
(Date:7/24/2014)... have yet to materialise. Yet, scientists are making ... computers faster. One such approach relies on quantum ... applying an electric field. A new study demonstrates ... quantum dots (TQDs) with electrical impulses can help ... should TQDs be used as quantum information units, ...
Breaking Biology Technology:Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4Nano-sized chip 'sniffs out' explosives far better than trained dogs 2
... , THOROLD, ON , ... innovative privately held Canadian biotechnology company focusing primarily on ... purification, today announced the launch of 10 new kits ... from blood, plasma and serum, including circulating nucleic acids. ...
... , Collaboration will further evaluate novel stem cell-derived ... genes relevant to disease progression , CAMBRIDGE, Mass. ... California Stem Cell, Inc. (CSC) and ALS Therapy Development ... expansion of their collaboration aimed at advancing a potential stem ...
... SANTA ROSA, Calif. , Feb. 2 Just in ... introduces the newest in their scientifically formulated product line: CIRCUTOL™ Cardiovascular ... in 1995 by integrative medicine pioneer, Dr. Isaac Eliaz ... being at the forefront of the latest developments in natural alternative health ...
Cached Biology Technology:Norgen Biotek Launches 10 New Kits for the Isolation of High-Quality Circulating Nucleic Acids from Blood, Plasma and Serum 2California Stem Cell and ALS Therapy Development Institute Extend Their Collaboration to Advance Potential Stem Cell Assisted Therapy for ALS 2California Stem Cell and ALS Therapy Development Institute Extend Their Collaboration to Advance Potential Stem Cell Assisted Therapy for ALS 3California Stem Cell and ALS Therapy Development Institute Extend Their Collaboration to Advance Potential Stem Cell Assisted Therapy for ALS 4Just in Time for Heart Health Month... TRIPLE Cardiovascular Health Support From EcoNugenics 2Just in Time for Heart Health Month... TRIPLE Cardiovascular Health Support From EcoNugenics 3
(Date:7/24/2014)... Scientists at The New York Stem Cell ... to creating a viable cell replacement therapy for ... , For the first time, NYSCF scientists generated ... samples of patients with primary progressive multiple sclerosis ... induce these stem cells into becoming oligodendrocytes, the ...
(Date:7/24/2014)... 24, 2014) Scientists at The New York ... step closer to creating a viable cell replacement ... cells. , For the first time, NYSCF ... from skin samples of patients with primary progressive ... protocol to induce these stem cells into becoming ...
(Date:7/24/2014)... identified two factors that characterize sustainable university and ... highly qualified physics teachers. Specifically, one or more ... education in combination with institutional motivation and commitment ... Technology, Engineering and Math (STEM) teacher shortages are ... the way for institutions seeking to increase the ...
Breaking Biology News(10 mins):NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2Creating sustainable STEM teacher preparation programs 2
... 25, 2010 - A first-of-its-kind study of a Caspian ... current harvest rates are four to five times higher ... results, which will be published in an upcoming issue ... conservation strategies for beluga sturgeon should focus on reducing ...
... A study involving the world,s deadliest substance has yielded a ... to more efficient strategies against toxins that may be used ... stings, and even some important chronic diseases. A ... agents that seek out Botulinum toxin molecules and bind to ...
... as they evolved over hundreds of generations to infect bacteria. ... the viruses evolved at a quicker rate and generated greater ... adapt to the viral infection. The study shows, for ... Valen was correct in his ,Red Queen Hypothesis,. The ...
Cached Biology News:New research shows fishery management practices for beluga sturgeon must change 2New research shows fishery management practices for beluga sturgeon must change 3Novel antitoxin strategy developed using 'tagged binding agents' 2Novel antitoxin strategy developed using 'tagged binding agents' 3Scientists reveal driving force behind evolution 2
... to the maintenance of appropriate levels ... important and diverse as those involved ... stress response, antigen presentation, modulation of ... cell cycle regulation, transcription, and signalling ...
... Proteolytic degradation is critical to the ... and regulatory proteins as important and ... metabolism, heat shock and stress response, ... receptors and ion channels, cell cycle ...
... Optics LIBS2000+ Spectrometers (sold separately) in the ... Chamber to offer numerous configuration options and ... include a high-power 1064 nm Nd:YAG laser, ... sample positioning, laser spot diameter control from ...
... Picking,A modified digital scanner serves as the ... the five standard rack positions on the ... micro well plates on the remaining two ... single spots by mouse-click on the scanned ...
Biology Products: